Free Trial
Notice: This company has been marked as potentially delisted and may not be actively trading.
NASDAQ:CNST

Constellation Pharmaceuticals (CNST) Stock Price, News & Analysis

Constellation Pharmaceuticals logo

About Constellation Pharmaceuticals Stock (NASDAQ:CNST)

Key Stats

Today's Range
$33.99
$33.99
50-Day Range
$33.63
$33.99
52-Week Range
$17.00
$39.30
Volume
N/A
Average Volume
940,325 shs
Market Capitalization
$1.63 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Constellation Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapeutics to address serious unmet medical needs in patients with cancers associated with abnormal gene expression or drug resistance. The company's lead product candidates include Pelabresib that is in Phase 3 clinical trials for the treatment of patients with myelofibrosis in combination with ruxolitinib. It is also developing CPI-0209 that is in Phase 1 dose escalation portion of a Phase 1/2 clinical trial to treat solid tumors; and CPI-482, which is in preclinical stage for cancer patients. The company was formerly known as Epigenetix, Inc. and changed its name to Constellation Pharmaceuticals, Inc. in March 2008. Constellation Pharmaceuticals, Inc. was incorporated in 2008 and is headquartered in Cambridge, Massachusetts.

Receive CNST Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Constellation Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

CNST Stock News Headlines

Plc Gsk's Net Worth
$20k in extra income?
My friend Alex Reid just might have created my favorite strategy right now. You see, Alex has figured out how to cut-the-corner so to speak, and be one of the laziest traders possible…. While still showing his traders how to target big money. This past year, his LIVE “lazy trade” alerts have delivered impressive results—and that’s only a fraction of the opportunities he’s shared. And that’s just just a quarter of the total trade alerts he’s sent out. The true total profit potential his beta-testers have had the chance to target is far larger than $20k.
VHCP Management II, LLC's Net Worth
Constellation Software
See More Headlines

CNST Stock Analysis - Frequently Asked Questions

Constellation Pharmaceuticals, Inc. (NASDAQ:CNST) announced its earnings results on Sunday, May, 9th. The company reported ($0.84) earnings per share for the quarter, missing the consensus estimate of ($0.79) by $0.05.

Constellation Pharmaceuticals (CNST) raised $80 million in an initial public offering (IPO) on Thursday, July 19th 2018. The company issued 5,300,000 shares at $14.00-$16.00 per share. J.P. Morgan, Jefferies and BMO Capital Markets served as the underwriters for the IPO and Oppenheimer was co-manager.

Based on aggregate information from My MarketBeat watchlists, some other companies that Constellation Pharmaceuticals investors own include Inovio Pharmaceuticals (INO), Kinross Gold (KGC), Sorrento Therapeutics (SRNE), Advanced Micro Devices (AMD), Axsome Therapeutics (AXSM), Gilead Sciences (GILD) and OPKO Health (OPK).

Company Calendar

Last Earnings
5/09/2021
Today
12/27/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical Preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:CNST
CUSIP
21036U206
Fax
N/A
Employees
154
Year Founded
N/A

Profitability

Net Income
$-126,360,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$8.63 per share

Miscellaneous

Free Float
N/A
Market Cap
$1.63 billion
Optionable
Not Optionable
Beta
2.59
2025 Gold Forecast: A Perfect Storm for Demand Cover

Unlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.

Get This Free Report

This page (NASDAQ:CNST) was last updated on 12/27/2024 by MarketBeat.com Staff
From Our Partners